ResultsIQ

ResultsIQ › Latest results › Sudeep Pharma Limited

Sudeep Pharma Limited Q1 FY27 results deck summary

NSE: SUDEEPPHRM · BSE: 544619

Results deck of 4 Aug 2026, summarised by AI from the filing.

Q1FY27 revenue from operations ₹158.3 cr, up 27% year-on-year, with PAT ₹40.6 cr, up 30%.

Key takeaways

  1. Revenue Revenue from operations ₹158.3 cr in Q1FY27, up 27% year-on-year from ₹124.9 cr.
  2. PAT Profit after tax ₹40.6 cr in Q1FY27, up 30% year-on-year from ₹31.3 cr.
  3. Greenfield Greenfield expansion remains on schedule with regulatory approvals progressing and customer qualification gaining momentum.
  4. SAM SAM Phase 1 on track for commissioning by March 2027; two additional strategic MoUs signed during the quarter.
  5. Headwinds Quarter faced geopolitical uncertainties, supply chain disruptions, intermittent gas supply constraints and elevated logistics costs.

Original filing on BSE

Sudeep Pharma Limited Q1 FY27 results

As filed: Revenue ₹158 cr, EBITDA ₹54.9 cr, PAT ₹40.6 cr, EBITDA margin 34.7%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹158 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹182 cr, EBITDA ₹62.6 cr, PAT ₹48.5 cr, EBITDA margin 34.3%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹182 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +26.2% in 29 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹172 cr, EBITDA ₹60.0 cr, PAT ₹47.7 cr, EBITDA margin 34.8%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹172 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −8.7% in 28 days (Nifty 500: −4.1%).
  • Q2 FY26: Revenue ₹163 cr, EBITDA ₹56.0 cr, PAT ₹47.0 cr, EBITDA margin 34.4%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹163 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −14.7% in 28 days (Nifty 500: −0.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Sudeep Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.